Drug Trial Radar · NCT07827612
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
161
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jul 2028
Study completion Mar 2031
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC). Safety tests will also be conducted. For each participant, the study will last up to 5 years.
Conditions
- Urinary Bladder Neoplasms
- Urologic Neoplasms
- Receptor, Fibroblast Growth Factor, Type 3
Interventions
VepugratinibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with LG IR NMIBC with Complete ResponseTime frame: Baseline, 2 Years
- Number of Participants with LG UTUC with Complete ResponseTime frame: Baseline, 2 Years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.